DK175135B1 - Forbedret fremgangsmåde, mellemprodukter og blandinger af mellemprodukter til fremstilling af trans-6-[2-(substitueret-pyrrol-1-yl)alkyl]pyran-2-on-inhibitorer af cholesterolsyntese - Google Patents

Forbedret fremgangsmåde, mellemprodukter og blandinger af mellemprodukter til fremstilling af trans-6-[2-(substitueret-pyrrol-1-yl)alkyl]pyran-2-on-inhibitorer af cholesterolsyntese Download PDF

Info

Publication number
DK175135B1
DK175135B1 DK199001970A DK197090A DK175135B1 DK 175135 B1 DK175135 B1 DK 175135B1 DK 199001970 A DK199001970 A DK 199001970A DK 197090 A DK197090 A DK 197090A DK 175135 B1 DK175135 B1 DK 175135B1
Authority
DK
Denmark
Prior art keywords
compound
formula
acid
ethyl
hydroxy
Prior art date
Application number
DK199001970A
Other languages
Danish (da)
English (en)
Other versions
DK197090A (da
DK197090D0 (da
Inventor
Donald Eugene Butler
Thomas Norman Nanninga
Carl Francis Deering
Bruce David Roth
Alan Millar
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26855024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK175135(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of DK197090D0 publication Critical patent/DK197090D0/da
Publication of DK197090A publication Critical patent/DK197090A/da
Application granted granted Critical
Publication of DK175135B1 publication Critical patent/DK175135B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK199001970A 1988-02-22 1990-08-17 Forbedret fremgangsmåde, mellemprodukter og blandinger af mellemprodukter til fremstilling af trans-6-[2-(substitueret-pyrrol-1-yl)alkyl]pyran-2-on-inhibitorer af cholesterolsyntese DK175135B1 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15843988A 1988-02-22 1988-02-22
US15843988 1988-02-22
US30373389 1989-02-01
US07/303,733 US5003080A (en) 1988-02-22 1989-02-01 Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
PCT/US1989/000719 WO1989007598A2 (en) 1988-02-22 1989-02-22 Improved process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US8900719 1989-02-22

Publications (3)

Publication Number Publication Date
DK197090D0 DK197090D0 (da) 1990-08-17
DK197090A DK197090A (da) 1990-10-04
DK175135B1 true DK175135B1 (da) 2004-06-14

Family

ID=26855024

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199001970A DK175135B1 (da) 1988-02-22 1990-08-17 Forbedret fremgangsmåde, mellemprodukter og blandinger af mellemprodukter til fremstilling af trans-6-[2-(substitueret-pyrrol-1-yl)alkyl]pyran-2-on-inhibitorer af cholesterolsyntese

Country Status (16)

Country Link
US (1) US5003080A (fi)
EP (2) EP0330172B1 (fi)
JP (2) JP2843627B2 (fi)
KR (1) KR970011578B1 (fi)
AT (1) ATE109777T1 (fi)
AU (2) AU634689B2 (fi)
CA (1) CA1330441C (fi)
DE (1) DE68917336T2 (fi)
DK (1) DK175135B1 (fi)
ES (1) ES2058356T3 (fi)
FI (2) FI94958C (fi)
HK (1) HK1000732A1 (fi)
IE (1) IE63994B1 (fi)
NZ (1) NZ228050A (fi)
PT (1) PT89774B (fi)
WO (1) WO1989007598A2 (fi)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
JP3171931B2 (ja) * 1992-06-02 2001-06-04 高砂香料工業株式会社 （Ｒ）−（−）−４−シアノ−３−ヒドロキシ酪酸ｔ−ブチルエステル及びその製造方法
JP3076154B2 (ja) 1992-08-13 2000-08-14 高砂香料工業株式会社 （３ｒ，５ｓ）−３，５，６−トリヒドロキシヘキサン酸誘導体及びその製造方法
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
GB9512837D0 (en) * 1995-06-23 1995-08-23 Zeneca Ltd reduction of ketone groups
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
WO1999032434A1 (en) * 1997-12-19 1999-07-01 Warner-Lambert Export Limited Process for the synthesis of 1,3-diols
CA2329893A1 (en) * 1998-04-30 1999-11-11 Kaneka Corporation Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
IN191236B (fi) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
CA2391357C (en) * 1999-12-17 2009-01-06 Warner Lambert Research And Development Ireland Limited A process for producing crystalline atorvastatin calcium
MXPA02004078A (es) 1999-12-17 2002-10-11 Warner Lambert Res & Dev Un proceso a escala industrial para producir sal de hemi calcio de trihidrato de atorvastatin cristalino.
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US20040014195A1 (en) * 1999-12-29 2004-01-22 Diversa Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) * 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US6528661B2 (en) 2000-11-16 2003-03-04 Teva Pharmaceutical Industries Ltd. Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1724256A3 (en) * 2001-01-09 2007-03-21 Warner-Lambert Company LLC Novel process for the synthesis of 5-(4-fluorphenyl)-1-2(2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl)-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
PL367943A1 (en) 2001-06-29 2005-03-07 Warner-Lambert Company Llc Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
WO2003004457A2 (en) * 2001-07-04 2003-01-16 Ciba Specialty Chemicals Holding Inc. Preparation process for atorvastatin and intermediates
DK1404642T3 (da) 2001-07-06 2010-05-17 Basf Se Fremgangsmåde til fremstillimg af 7-amino-syn-3,5-dihydroxyheptansyrederivater, mellemprodukter derfor og fremgangsmåder til deres fremstilling
PT1404642E (pt) 2001-07-06 2010-03-29 Basf Se Processo para a preparação de derivados do ácido 7-amino sin 3,5-dihidroxi heptanoico, intermediários respectivos e métodos para a sua preparação
HUP0401014A2 (hu) 2001-07-06 2004-08-30 Teva Pharmaceutical Industries Ltd. Eljárás 7-amino-szin-3,5-dihidroxi-heptánsavszármazékok előállítására, 6-ciano-szin-3,5-dihidroxi-hexánsav származékokon keresztül
EP2292600A1 (en) 2001-07-30 2011-03-09 Dr. Reddy's Laboratories Ltd. Crystaline forms VI and VII of atorvastatin calcium
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
US7563911B2 (en) * 2001-08-31 2009-07-21 Morepen Laboratories Ltd. Process for the preparation of amorphous atorvastin calcium salt (2:1)
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
EP1451179A1 (en) * 2001-11-22 2004-09-01 Ciba SC Holding AG Pyrrole synthesis
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
IL163594A0 (en) * 2002-02-19 2005-12-18 Teva Pharma Processes for desolvating solvates of atorvastatinhemi-calcium and atorvastatin hemi-calcium essentially free of organic solvent
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
AU2003251523A1 (en) * 2002-06-13 2003-12-31 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
CA2494269A1 (en) * 2002-08-06 2004-02-19 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
US20060122403A1 (en) * 2002-09-03 2006-06-08 Sanjay Suri Atorvastatin calcium form vi or hydrates thereof
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
WO2004046105A2 (en) * 2002-11-15 2004-06-03 Teva Pharmaceutical Industries Ltd. Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
WO2004089894A1 (en) * 2003-04-14 2004-10-21 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
DK1620423T3 (da) * 2003-05-02 2008-05-26 Dsm Ip Assets Bv Fremgangsmåde til fremstillingen af (4-hydroxy-6-oxotetrahydropyran-2-yl) acetonitril og derivater deraf
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
JP2007500219A (ja) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US7414140B2 (en) 2003-06-18 2008-08-19 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
WO2005012246A1 (en) 2003-07-25 2005-02-10 Avecia Pharmaceuticals Limited Process and intermediate compounds useful in the preparation of statins, particularly atorvastatin
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
US7557238B2 (en) * 2003-09-18 2009-07-07 Biocon Limited Process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
CA2645396A1 (en) * 2003-12-24 2005-07-14 Teva Pharmaceutical Industries, Ltd Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
AU2004309313A1 (en) * 2003-12-29 2005-07-14 Lek Pharmaceuticals D.D. Process for preparing amorphous (4R-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
EP1577297A1 (en) 2004-03-17 2005-09-21 Ranbaxy Laboratories, Ltd. Process for the production of atorvastatin calcium in amorphous form
JP2007532622A (ja) * 2004-04-16 2007-11-15 ファイザー・プロダクツ・インク 非晶質アトルバスタチン・カルシウムの形成方法
US7875731B2 (en) * 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
CA2672554C (en) 2004-07-20 2012-01-03 Warner-Lambert Company Llc Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2006032959A2 (en) * 2004-08-06 2006-03-30 Glenmark Pharmaceuticals Limited Processes for the preparation of pyrrole derivatives
JP2008510797A (ja) * 2004-08-26 2008-04-10 バイオコン・リミテッド ４−フルオロ−α−［２−メチル−１−オキソプロピル］γ−オキソ−Ｎ−β−ジフェニルベンゼンブタンアミドの製造方法
US7645888B2 (en) * 2004-08-27 2010-01-12 Biocon Limited Process for the production of amorphous atorvastatin calcium
BRPI0519996A2 (pt) 2004-10-28 2009-04-07 Warner Lambert Co processo para formar atorvastatina amorfa
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
CA2498978A1 (en) * 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
RO123642B1 (ro) * 2005-04-08 2015-07-30 Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag Procedeu pentru prepararea unei noi forme cristaline polimorfe a sării de hemicalciu a atorvastatinului
EP1922301A1 (en) * 2005-09-09 2008-05-21 Pfizer Science and Technology Ireland Limited Preparation of an atorvastatin intermediate
DE602005014686D1 (de) * 2005-09-09 2009-07-09 Pfizer Science & Tech Ltd Herstellung eines atorvastatin-zwischenprodukts
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
CA2633268A1 (en) * 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2007096751A1 (en) * 2006-02-21 2007-08-30 Cadila Healthcare Limited Process for the preparation of atorvastatin calcium
KR20070116963A (ko) * 2006-03-01 2007-12-11 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미 칼슘 결정형의 제조 방법
WO2008075165A1 (en) * 2006-12-19 2008-06-26 Pfizer Products Inc. Novel process for the synthesis of [r-(r*, r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid or a pharmaceutically acceptable salt thereof
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
KR100881617B1 (ko) 2007-02-22 2009-02-17 (주) 성운파마코피아 아토바스타틴 제조를 위한 중간체 및 그의 제조방법
DK2115153T3 (da) 2007-03-01 2013-09-08 Bp Corp North America Inc Nitrilaser, nucleinsyrer som koder for dem og fremgangsmåder til at fremstille og anvende disse
GB0711250D0 (en) 2007-06-12 2007-07-18 Cbz Chemicals Ltd Furanose derivatives
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
KR100921195B1 (ko) * 2007-10-25 2009-10-13 주식회사 대웅제약 아토르바스타틴의 제조 방법
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
KR100850558B1 (ko) * 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
EP2279167B1 (en) * 2008-05-29 2012-09-19 Arch Pharmalabs Limited NOVEL PROCESS FOR THE PREPARATION OF 4-FLUORO-ALPHA-Ý2-METHYL -1-OXOPROPYL¨-GAMMA-OXO-N-ß-DIPHENYLBENZENEBUTANAMIDE AND PRODUCTS THEREFROM
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
KR20120011249A (ko) 2010-07-28 2012-02-07 주식회사 경보제약 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
EP2614057B1 (en) * 2010-09-09 2015-10-21 DSM Sinochem Pharmaceuticals Netherlands B.V. Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
US20130178636A1 (en) * 2010-09-16 2013-07-11 Dsm Sinochem Pharmaceuticals Netherlands B.V. Esters of hexanoic acids as intermediates for the preparation of atorvastatin
CN102127060B (zh) * 2010-12-17 2013-12-04 蚌埠丰原医药科技发展有限公司 一种阿托伐他汀钙中间体的制备方法
WO2013004591A1 (en) 2011-07-01 2013-01-10 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
US20210008084A1 (en) 2017-10-16 2021-01-14 Tsinghua University Mevalonate pathway inhibitor and pharmaceutical composition thereof
CN111909048B (zh) * 2020-09-07 2021-03-16 浙江宏元药业股份有限公司 一种多组分一锅法合成阿托伐他汀钙中间体的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960941A (en) * 1973-04-04 1976-06-01 Ethyl Corporation 3-Hydroxy-3,4-dicarbamoylbutyric acid and salts
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi

Also Published As

Publication number Publication date
NZ228050A (en) 1992-01-29
FI93958B (fi) 1995-03-15
AU635171B2 (en) 1993-03-11
EP0330172A3 (en) 1989-12-13
EP0330172B1 (en) 1994-08-10
US5003080A (en) 1991-03-26
IE890391L (en) 1989-08-22
DK197090A (da) 1990-10-04
FI94958C (fi) 1995-11-27
WO1989007598A2 (en) 1989-08-24
FI93958C (fi) 1995-06-26
ATE109777T1 (de) 1994-08-15
CA1330441C (en) 1994-06-28
FI904118A0 (fi) 1990-08-20
AU634689B2 (en) 1993-02-25
FI94958B (fi) 1995-08-15
DE68917336T2 (de) 1994-12-01
JP3009139B2 (ja) 2000-02-14
PT89774B (pt) 1994-03-31
JPH03502798A (ja) 1991-06-27
AU1601892A (en) 1992-07-09
DK197090D0 (da) 1990-08-17
DE68917336D1 (de) 1994-09-15
FI941550A (fi) 1994-04-05
JPH10195071A (ja) 1998-07-28
AU1601792A (en) 1992-07-09
ES2058356T3 (es) 1994-11-01
KR970011578B1 (en) 1997-07-12
HK1000732A1 (en) 1998-04-24
IE63994B1 (en) 1995-06-28
KR900700478A (ko) 1990-08-13
WO1989007598A3 (en) 1989-11-02
EP0448552A1 (en) 1991-10-02
PT89774A (pt) 1989-10-04
JP2843627B2 (ja) 1999-01-06
EP0330172A2 (en) 1989-08-30
FI941550A0 (fi) 1994-04-05

Similar Documents

Publication Publication Date Title
DK175135B1 (da) Forbedret fremgangsmåde, mellemprodukter og blandinger af mellemprodukter til fremstilling af trans-6-[2-(substitueret-pyrrol-1-yl)alkyl]pyran-2-on-inhibitorer af cholesterolsyntese
US5280126A (en) Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
CA1242721A (en) Trans-6-¬2-substituted pyrrol-1-yl)alkyl|-pyran -2- one inhibitors of cholesterol synthesis
Hart et al. . alpha.-Acylamino radical cyclizations: syntheses of isoretronecanol
Lee et al. Acyl tetramic acids. 6. Synthesis of 3-dienoyl tetramic acids related to streptolydigin and tirandamycin
JP2011514352A (ja) サリノスポラミドａおよびその類似体の全合成
Valeev et al. Stereochemical aspects of the beckman rearrangement of oximes of levoglucosenone and its dihydro derivative. Enantioselective synthesis of (+)-γ-pelargonolactone
EP0494209A1 (en) Cyclic peroxyacetal lactone, lactol and ether compounds
Nagarapu et al. Tin (II) chloride catalyzed synthesis of pyranoquinolines, phenanthridinone and phenanthridine derivatives
EP0011057B1 (fr) Procédé de synthèse de la vincadifformine et des dérivés apparentés à celle-ci, produits intermédiaires obtenus pendant cette synthèse et procédé pour leur préparation
AU621874B2 (en) Improved process for trans-6-(2-(substituted-pyrrol-1-yl) alkyl)pyran-2-one inhibitors of cholesterol synthesis
KR970011579B1 (ko) 콜레스테롤 합성 억제제인 트란스-6-[2-(치환 피롤-1-일)알킬]피란-2-온의 개량된 제조방법
NO177706B (no) Forbedret fremgangsmåte for fremstilling av trans-6-[2- (substituert-pyrrol-yl) alkylÅ pyran-2-on-inhibitorer for kolesterolsyntese
Chang et al. Formal synthesis of (±)-hop ether,(±)-isoboonein, and (±)-iridomyrmecin
NZ238844A (en) 4,5-diphenyl-3-phenylaminocarbonyl-pyrrole derivatives
JPH0267287A (ja) ペネムの製法
JPH0288575A (ja) 置換融合ピロール
NO177423B (no) Forbedret fremgangsmåte for fremstilling av trans-6-[2-(substituert-pyrrol-yl)alkylÅpyran-2-on-inhibitorer for kolesterolsyntese
AU2011211338A1 (en) Substituted pyrrole derivatives and their use as HMG-CO inhibitors
JPS5815982A (ja) （４ｓ又は４ｒ）４置換２，８−ジオキサビシクロ〔３，３，１〕ノナン
PL193124B1 (pl) Nowe hydroksylaktony i sposób otrzymywania nowych hydroksylaktonów

Legal Events

Date Code Title Description
PUP Patent expired